Current protein-based anti-angiogenic therapeutics

Chakrabarti, Sanjukta, Barrow, Colin J., Kanwar, Rupinder K., Ramana, Venkata and Kanwar, Jagat R. 2014, Current protein-based anti-angiogenic therapeutics, Mini-reviews in medicinal chemistry, vol. 14, no. 3, pp. 291-312.

Attached Files
Name Description MIMEType Size Downloads

Title Current protein-based anti-angiogenic therapeutics
Author(s) Chakrabarti, Sanjukta
Barrow, Colin J.
Kanwar, Rupinder K.
Ramana, Venkata
Kanwar, Jagat R.
Journal name Mini-reviews in medicinal chemistry
Volume number 14
Issue number 3
Start page 291
End page 312
Total pages 22
Publisher Bentham Science Publishers
Place of publication Bussum, The Netherlands
Publication date 2014-02-21
ISSN 1389-5575
1875-5607
Keyword(s) angiogenesis
anti-angiogenic drugs
clinical trials
Fc-fusion proteins
VEGF
VEGF receptors
Summary  Angiogenesis is a complex multistep process of formation of new blood vessels. Interactions between several cellular factors including growth factors, cytokines and haematopoietic factors lead to activation of various cellular pathways, finally resulting in extracellular matrix (ECM) degradation, endothelial cell proliferation, survival and migration. Normally, angiogenesis is an essential requirement for vascular development in growing embryos as well as in adult tissues, where this process depends on the intricate balance between the activities of the pro- and anti-angiogenic factors. Abnormal angiogenesis results in aberrant vasculature leading to various pathological conditions. The most important factor implicated in angiogenic processes in vascular endothelial growth factor (VEGF) and its family of ligands and receptors. Several anti-angiogenic drugs have been developed and many more are currently in different phases of clinical trials, which target various angiogenesis-inducing agents, including VEGF, VEGF receptors, angiopoietins and ECM components such as integrins. Anti-angiogenic therapy can be divided into gene-based therapy and protein-based therapy. Gene-based therapies include use of antisense oligonucleotides, siRNA, aptamers, catalytic oligonucleotides including ribozymes and DNAzymes and transcription decoys. Protein-based therapeutics includes monoclonal antibodies, peptidomimetics, fusion proteins and decoy receptors. The later class of therapeutics has several advantages over gene-based and small molecule drugs, including specificity and complexity in functions, better tolerability, less interference with normal biological processes and lesser adverse effects due to decreased immune response by virtue of being mostly body's natural proteins. This review provides a comprehensive overview of angiogenesis and on the current protein-based anti-angiogenic therapeutics under research and in the clinic.
Language eng
Field of Research 111207 - Molecular Targets
111204 - Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Socio Economic Objective 920102 - Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2014, Bentham Science Publishers
Persistent URL http://hdl.handle.net/10536/DRO/DU:30062739

Document type: Journal Article
Collections: School of Medicine
School of Life and Environmental Sciences
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 39 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 30 Apr 2014, 13:57:19 EST by Rupinder Kanwar

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.